港股异动 | 宜明昂科-B(01541)盘中异动拉升涨近3% 子公司IMC-002针对系统性红斑狼疮(SLE)的临床研究申请获国家药品监督管理局批准

智通财经06-19

智通财经APP获悉，宜明昂科-B(01541)盘中异动拉升涨近3%，截至收盘涨0.71%，报14.26港元。值得关注的是，盘后根据公司微信公众号消息称，公司全资子公司宜明凯尔IMC-002(CD47xCD20 mAb-Trap)项目针对系统性红斑狼疮(SLE)的临床研究申请(IND)获得国家药品监督管理局(NMPA)批准。据悉，相对于CD20单抗药物，CD47xCD20双靶点药物IMC-002针对...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2444427388?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-06-19 18:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2444427388","market":"us","top_or_hot":-1,"title":"港股异动 | 宜明昂科-B(01541)盘中异动拉升涨近3% 子公司IMC-002针对系统性红斑狼疮(SLE)的临床研究申请获国家药品监督管理局批准","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，宜明昂科-B(01541)盘中异动拉升涨近3%，截至收盘涨0.71%，报14.26港元。值得关注的是，盘后根据公司微信公众号消息称，公司全资子公司宜明凯尔IMC-002(CD47xCD20 mAb-Trap)项目针对系统性红斑狼疮(SLE)的临床研究申请(IND)获得国家药品监督管理局(NMPA)批准。据悉，相对于CD20单抗药物，CD47xCD20双靶点药物IMC-002针对...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1137502.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 宜明昂科-B(01541)盘中异动拉升涨近3% 子公司IMC-002针对系统性红斑狼疮(SLE)的临床研究申请获国家药品监督管理局批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 宜明昂科-B(01541)盘中异动拉升涨近3% 子公司IMC-002针对系统性红斑狼疮(SLE)的临床研究申请获国家药品监督管理局批准\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-19 18:56 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1137502.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，宜明昂科-B(01541)盘中异动拉升涨近3%，截至收盘涨0.71%，报14.26港元。值得关注的是，盘后根据公司微信公众号消息称，公司全资子公司宜明凯尔IMC-002(CD47xCD20 mAb-Trap)项目针对系统性红斑狼疮(SLE)的临床研究申请(IND)获得国家药品监督管理局(NMPA)批准。据悉，相对于CD20单抗药物，CD47xCD20双靶点药物IMC-002针对...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1137502.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"YANG","symbol_name":"三倍做空富时中国ETF-Direxion","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1137502.html","article_id":"2444427388","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2444427388","pubTimestamp":1718794561,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，宜明昂科-B盘中异动拉升涨近3%，截至收盘涨0.71%，报14.26港元。据悉，相对于CD20单抗药物，CD47xCD20双靶点药物IMC-002针对SLE病人外周血B细胞具有更强的清除作用。另外有文献报道，体内敲除CD47可显著降低狼疮肾炎模型动物蛋白尿水平，同时显著延长疾病动物的寿命，因此公司相信IMC-002对中重度SLE预期会有很好的临床疗效。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"YANG":"三倍做空富时中国ETF-Direxion","07226":"XL二南方恒科","HSCEI":"国企指数","BK1161":"生物科技","SLE":"Super League Gaming Inc.","HSTECH":"恒生科技指数","01541":"宜明昂科-B","BK4077":"互动媒体与服务"},"translate_title":"Changes in Hong Kong stocks Yiming Angke-B (01541) rose nearly 3% in intraday changes Subsidiary IMC-002's clinical research application for systemic lupus erythematosus (SLE) was approved by the State Drug Administration","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01541":1,"07226":1,"HSCEI":1,"HSTECH":1,"SLE":1,"YANG":1},"content_text":"智通财经APP获悉，宜明昂科-B(01541)盘中异动拉升涨近3%，截至收盘涨0.71%，报14.26港元。值得关注的是，盘后根据公司微信公众号消息称，公司全资子公司宜明凯尔IMC-002(CD47xCD20 mAb-Trap)项目针对系统性红斑狼疮(SLE)的临床研究申请(IND)获得国家药品监督管理局(NMPA)批准。据悉，相对于CD20单抗药物，CD47xCD20双靶点药物IMC-002针对SLE病人外周血B细胞具有更强的清除作用。另外有文献报道(J Pathol 2015; 237: 285–295)，体内敲除CD47可显著降低狼疮肾炎模型动物蛋白尿水平，同时显著延长疾病动物的寿命，因此公司相信IMC-002对中重度SLE预期会有很好的临床疗效。公司创始人、董事长田文志博士表示：“IMC-002是一种CD47xCD20双靶点抗体-受体重组蛋白(mAb-Trap)，体外实验表明对B细胞杀伤效应显著强于利妥昔单抗，IMC-002(1ug/ml)能显著引起SLE病人外周血中CD19+ B细胞的耗竭，因此我们认为对B细胞相关自免性疾病预期会有良好疗效。我们计划将在多个适应症开展进一步探索性研究，期待给广大的自身免疫系统疾病患者带来福音。”","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2444427388"}